Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection

On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lattanzio, Natalia, Acosta-Diaz, Cristina, Villasmil, Ricardo J, Kirkland, Zachary, Bass, Caitlin, Yenari, Sage, Conte, Jorge, Dawkins, Kevin, Fonseca, Tamela, Grimes, Cindy, Stewart, Angie, Geary, Mary E, Vore, Harold, Hamad, Karen, Wiese-Rometsch, Wilhelmine, Fiorica, James, Gordillo, Manuel, Mercado, Roberto, Voelker, Kirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405359/
https://www.ncbi.nlm.nih.gov/pubmed/34513370
http://dx.doi.org/10.7759/cureus.16746
Descripción
Sumario:On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health.

Ejemplares similares